Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Retatrutide for Sale > Epithalon peptide in stock Customize Peptides
Epithalon peptide in stock Customize Peptides buy - large image1
Epithalon peptide in stock Customize Peptides buy - image1
Epithalon peptide in stock Customize Peptides buy - image2
Epithalon peptide in stock Customize Peptides buy - image3
Epithalon peptide in stock Customize Peptides buy - image4
Epithalon peptide in stock Customize Peptides buy - image5

Epithalon peptide in stock Customize Peptides

TDS 7470 Inquiries

Unit Price:

$1.02-1.2/UNIT FOB

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

shenzhen

Brand:

shanxi grace

Packaging:

2mg, 5mg 10mg 15mg 30mg Per Vial, 10vials/box

Price valid (until):

2031-02-28

This product has been removed from the shop temporarily..
Company Type:
Trader
Location:
China
Payment Terms:
100% TT in advance
Average Lead Time:
10 days
Qualification:
Main Products:

peptide,humic acid

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


       Product Detail  



    Items Specifications
    Purity 99%
    Appearance White powder
    Application Healthcare
    Package 1box=10 vials,or 1g/bottle
    Storage Store in refrigerator at 4°C, tightly sealed, away from heat, light and moisture.
    Retest Date 2 years

    Product shows

    Shop Epithalon peptide in stock Customize Peptides-Detailed Image 1 Shop Epithalon peptide in stock Customize Peptides-Detailed Image 2 Shop Epithalon peptide in stock Customize Peptides-Detailed Image 3

    Company Profile   

     

    Shanxi grace hitech Technology Co., Ltd. was founded in 2020 has strong research and development capabilities and superb synthesis technology, as well as advanced quality control measures. We effectively promote joint ventures and cooperation with major enterprises and manufacturers, and serve the society and the majority of users with the idea of industrialized development.

    We always adhere to the market demand-oriented, and constantly synthesize new chemical products and pharmaceutical intermediates with high technical content, mainly exported to the United States, India, South Africa, Nigeria and many other countries and regions, with rich experience in export, to ensure the safety of transportation, and to be able to let every customer receive the goods safely as early as possible.


    Why choose us

    Rich experience
    1. Our company is a professional and leading factory with many years of experience in the pharmaceutical field in China.
    2. We have good feedback from customers all over the world.
    OEM service
    1.Add customer logo
    2. Redesign labels and packaging boxes according to customer requirements
    3. Bottle cap color can be customized
    Shipping service
    1. Shipped within 48 hours after payment is received.
    2. Small orders are shipped via express door-to-door.
    3. The goods arrive in 7-10 days
    24 hours service
    1.Reply your inquiry within 10 hours
    2. Continuously track goods and update information to customers
    3. After-sales service at any time


    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Certificates

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Polypeptide

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    peptide,humic acid

    Location:

    No. 601, Unit 2, Building 5, South District, Beizhang Community, Xiaodian District, City

    Payment Terms:

    100% TT in advance

    Average lead Time:

    10 days

    Year of Establishment:

    2024

  • Inquiry History
    7470 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide

    100 PCS Oct 27, 2026
    New Zealand

    Retatrutide

    20 PCS Oct 27, 2026
    Netherlands

    Retatrutide

    100 20' Fcl Oct 27, 2026
    United States

    Retatrutide

    300 MG Oct 27, 2026
    Canada

    Retatrutide

    1 G Oct 26, 2026
    Switzerland

    Retatrutide

    1 KG Oct 26, 2026
    United States

    Retatrutide

    10 MG Oct 26, 2026
    Australia

    Retatrutide

    30 MG Oct 26, 2026
    United States

    Retatrutide

    30 MG Oct 26, 2026
    United States

    Tesa

    2 MG Oct 25, 2026
    Colombia

    Retatrutide

    15 MG Oct 25, 2026
    United States

    Retatrutide

    10 G Oct 25, 2026
    Canada

    Retatrutide

    1 KG Oct 25, 2026
    United Kingdom

    Retatrutide

    1 G Oct 25, 2026
    Netherlands

    Retatrutide

    10 MG Oct 25, 2026
    Australia

    Retatrutide

    10 MG Oct 25, 2026
    Netherlands

    Retatrutide

    20 MG Oct 25, 2026
    Germany

    Retatrutide

    1 KG Oct 25, 2026
    United Kingdom

    Retatrutide

    10 G Oct 25, 2026
    United States

    Retatrutide

    20 MG Oct 25, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.